(Adnkronos) - L’indicazione terapeutica dell’anticorpo farmaco coniugato sacituzumab govitecan è da oggi estesa alle pazienti con tumore al seno metastatico HR+/HER2- e, in seconda linea, alle donne con carcinoma alla mammella metastatico triplo negativo. Il via libera di Aifa all’estensione di indicazione del farmaco giunge dopo i risultati positivi degli studi clinici Tropics-02 e Ascent, che evidenziano una riduzione del rischio di progressione di malattia, così come di quello di morte, rispetto alla chemioterapia standard. Se ne è parlato in occasione dell’incontro con la stampa organizzato oggi a Milano da Gilead Sciences Italia ed intitolato ‘Gilead per le donne. Nuove prospettive nel tumore al seno metastatico’.
Category
🗞
NewsTranscript
00:00Thanks to a better knowledge of the biology of the mammary tumor, which has allowed us
00:08to understand that there are at least three different subtypes of this carcinoma with
00:12different prognosis, different treatment needs and thanks to the innovation in the therapeutic
00:16field, a significant improvement of the life expectancy of patients with metastatic mammary
00:23tumor has been determined.
00:24The only subtype in which no improvement of survival has been observed is the so-called
00:29triple negative metastatic mammary tumor and it is precisely in this subgroup of patients
00:35that this new drug, Sacitutum amagovitagan, has shown to improve the life expectancy,
00:41therefore to improve survival, to improve the time in which we are able to maintain
00:46the metastatic disease under control and also to improve the quality of life compared
00:52to standard chemotherapeutic treatments.
00:54This drug, Sacitutum amagovitagan, can also be used in an earlier phase of the history
01:02of these women with the so-called triple negative mammary tumor and therefore we expect
01:07that this earlier use can further improve the therapeutic results obtained so far.
01:14However, Sacitutum amagovitagan is also a new indication that the possibility of using it
01:19also in the subgroup with positive hormonal receptors, which is the majority of cases
01:25of metastatic mammary cancer.
01:27Also in these patients, compared to standard chemotherapy, this innovative drug, which
01:32is a conjugated antibody, has shown to improve both survival and quality of life.
01:38So it is an important therapeutic option for practically most women who today
01:45in Italy live with a diagnosis of metastatic mammary cancer.
01:49With the Gilead for Women meeting, new prospects in metastatic breast cancer
01:53taking place in Milan, Gilead Science Italy celebrated the double result obtained with
01:58the indication extension of the drug.
02:01Our mission from the beginning, from the age of 35, is really to revolutionize the cures
02:06of serious diseases.
02:07We did it in HIV, we did it in hepatitis, in COVID, but also on oncology and mato-oncology,
02:13now for three years also in oncology alone.
02:15We arrived with a therapy, a truly innovative drug-conjugated antibody to the metastatic
02:20breast cancer, triple negative, with which we have already helped treat about 2,000 women
02:27in Italy, but obviously this path continues with what we are announcing today, but it
02:32will also continue in the future, because we also want to continue to strengthen our
02:37commitment in this area of solid oncology.
02:39We currently have about 30 clinical studies globally, 15 here in Italy, where we do
02:46a lot of research and we hope by 2030 to arrive with 29 indications, both in breast cancer
02:53as well as lung cancer, genitourinary and other types of tumors.